FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival.
Also in this 8-page issue: Tony Hunter, Raymond DuBois win AACR Landon prizes.
Funding opportunities: ASCO breast cancer research award; Lustgarten Foundation prostate cancer research award; NCI program announcements available.
Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - From the chairs of ECOG-ACRIN: A perspective on indirect costs
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty